The approval of Cobenfy has ushered in a new era of R&D, fuelling innovation in novel mechanisms of action, muscarinics, and beyond. Having spoken to incredible R&D experts from the likes of Alkermes, Boehringer Ingelheim, Monument Therapeutics, Teva Pharmaceuticals and Gilgamesh Pharmaceuticals, I am excited to launch the?inaugural Innovation in Psychosis Therapeutics Summit (June, Boston)! ? View the brand-new agenda and full speaker faculty here: https://ter.li/atz3lr ? Don’t miss out on the opportunity to hear from the brand-new speaker faculty: Steven Paul, Founder & Board Chair, Seaport Therapeutics (former CEO & CSO of Karuna Therapeutics) Andrew Miller, Founder & President, Research & Development, Karuna Therapeutics Jenny Barnett, Chief Executive Officer, Monument Therapeutics Adam Savitz, Chief Medical Officer, Alto Neuroscience Zhong Zhong, Chief Scientific Officer, Ovid Therapeutics Pablo Lapuerta, Chief Executive Officer, 4M Therapeutics Neel Desai, Business Development & Licensing, Biogen robert goldman, Senior Vice President, Head, Medical Affairs, MapLight Therapeutics Shaheen E Lakhan, MD, PhD, FAAN, Chief Medical Officer, Click Therapeutics Harri J?rvel?inen, DVM, PhD, MBA, DABT, ERT, Prof, Chief Executive Officer, Aivo Biosciences Dr Kiri Granger, Chief Scientific Officer, Monument Therapeutics Mikhail Kalinichev, Head of Translational Science, Neurosterix Laxminarayan Bhat, Ph.D., Chief Executive Officer, Reviva Pharmaceuticals Jonathan C. Javitt, M.D., M.P.H., Founder, NRx Pharmaceuticals Hadile Ounallah-Saad, Head of Innovation, Early-Stage Pipeline, Clexio Biosciences Daniel Smith, Head of Translational Medicine, Alkermes Paulo Lizano, Neuropsychiatrist, Physician-Scientist, Assistant Professor in Psychiatry, Harvard Medical School Hannah Brown, Clinical Associate Professor, Psychiatry, Boston University We hope to see you alongside fellow psychosis R&D leaders as they unite to advance beyond atypical antipsychotics to alleviate side effects & revolutionize the treatment of psychotic symptoms in neuropsychiatric, neurodegenerative & neurodevelopmental disorders. ? #Psychosis #DrugDevelopment #Neuropsychiatry #Biotech #Pharma #Schizophrenia?
Reviva Pharmaceuticals
生物技术研究
Cupertino，California 1,755 位关注者
Next Generation Therapeutics to successfully address central nervous system, metabolic and respiratory diseases.
关于我们
NASDAQ: RVPH Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a publicly traded, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic and inflammatory diseases. The leadership and management team is comprised of highly successful and experienced professionals from the pharmaceutical industry and have a demonstrated track record of taking drugs through the development process to the global market. Speed without sacrificing quality is one of the hallmarks of Reviva’s product development model. The company has a strong patent portfolio and promising multiple products in the pipeline at various stages of development. The company’s lead product RP5063 is a multimodal neuromodulator which has successfully completed the global Phase 2 clinical trials and has shown a superior efficacy and safety profile for schizophrenia and schizo affective disorder. After having a very successful End of Phase 2 ( EOP2 ) meeting with U.S. FDA, the company is now preparing to start the global Phase 3 clinical trials for RP5063 in acute and maintenance phase schizophrenia patients. The company is also planning to develop RP5063 for bipolar disorder, major depressive disorder (MDD), Alzheimer’s psychosis/agitation (ADP), Parkinson’s psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD) and autism spectrum.
- 网站
-
https://www.revivapharma.com
Reviva Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cupertino，California
- 类型
- 上市公司
地点
-
主要
获取路线
10080 N Wolfe Rd
Suite SW3-200
US，California，Cupertino，95014
Reviva Pharmaceuticals员工
动态
-
Founder & CEO, Laxminarayan Bhat, Ph.D., participated in the Tackling Mental Health Through New Targets and Endpoints Progress panel at the BIO CEO & Investor Conference 2025 in New York. Dr. Bhat joined a distinguished group of industry leaders to discuss the future of mental health treatment, highlighting the importance of novel therapeutic targets and innovative clinical endpoints in addressing unmet patient needs. Collaboration remains essential in driving meaningful progress and advancing groundbreaking therapies. A special thank you to the panelists and attendees for an engaging and insightful discussion. Pictured from left to right: Boobalan Pachaiyappan, Ph.D. (Managing Director, Senior Biotech Analyst; Roth Capital Partners); Joshua Gordon MD, Ph.D., (Professor and Chair Columbia University, Executive Director, New York State Psychiatric Institute); Ken Kramer, PhD (Vice President and Head of Medical Affairs, Neuropsychiatry Therapeutic Area; BMS); Laxminarayan Bhat, Ph.D. (Founder & CEO; Reviva Pharmaceuticals); Srinivas Rao, MD Ph.D., (Co-founder and CEO; atai Life Sciences) Not Pictured: Amy Nguyen (Vice President, Business Development and Client Management,?CTI Clinical Research) #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS #BIO2025
-
-
Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present at the Oppenheimer 35th?Annual Healthcare Life Sciences Conference, taking place virtually February 11-12, 2025. *Oppenheimer 35th?Annual Healthcare Life Sciences Conference *Format: Corporate update *Date: Wednesday, February 12, 2025 *Time: 2:40 p.m. ET *Location: Virtual *Webcast Link: https://lnkd.in/gWGaaxQ9 View press release: https://lnkd.in/gWMNSnec #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS #OPCOLifeSciences
-
Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY. *2025 BIO CEO & Investor Conference *Panel Title: Tackling Mental Health through New Targets and Endpoints Progress *Date: Tuesday, February 11, 2025 *Time: 1:00 p.m. ET *Location: New York, NY *Registration Link: https://lnkd.in/e7spAj42 View press release: https://lnkd.in/gASfwKiZ Biotechnology Innovation Organization #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS #BIO2025?
-
Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit on Monday, January 13, 2025, at 12:30 p.m. ET. *Lytham Partners 2025 Investor Healthcare Summit *Date: Monday, January 13, 2025 *Time: 12:30 p.m. ET *Registration Link: https://lnkd.in/gNZ5fcVc Please see our press release for more details: https://lnkd.in/gdjnRMv4 #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS
-
Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will attend the Neuroscience Innovation Pharma Partnering Summit, taking place February 18-19, 2025, in Boston. This new forum is gathering a targeted critical mass of business decision makers across neuroscience targets, modalities and diseases, in the context of disruptive scientific discussion, to increase the alignment between companies like ours, looking for collaborations with this community, specifically. ? View Agenda - https://ter.li/lnp5vs Register - ?https://ter.li/f92zpl #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #Brilaroxazine #Schizophrenia #CNS #Neuroscience #NeurosciencePartnering?#NeuroscienceInnovation?
-
-
Today we announced positive preliminary topline data for the open-label extension portion of our ongoing Phase 3 RECOVER study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. * Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year * Generally well-tolerated with low rates of adverse events and discontinuation * Full data set from open-label extension of RECOVER expected in Q1 2025 Read our press release for further details:?https://lnkd.in/giZqyQ3u #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS #clinicaltrials
-
Today we reported financial results for the third quarter ended September 30, 2024 and summarized recent business highlights, including: – 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative symptoms and other key symptom domains of schizophrenia – Topline data from OLE trial expected in December 2024 Please see our press release for full details: https://lnkd.in/gXrEgG9Y #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS #earnings
-
Today we announced an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. Key highlights included: – 108 patients have completed 1-year of treatment – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – Topline data from 1-year OLE trial now expected in December 2024 Read our press release for full details:?https://lnkd.in/gd9AMk55 #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS #clinicaltrials
-
Reviva to present positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial at the CNS Summit 2024 on Tuesday, November 12, 2024. *Title: Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine *Poster Board: 10 *Date and Time: Tuesday, November 12th from 5:00 – 7:00 PM ET *Presenter: Dr. Jan Sedway, WCG Clinical *Abstracts and additional details can be found at the CNS Summit 2024 website at https://cnssummit.org/ #RVPH #RevivaPharma #RevivaPharmaceuticals #Reviva #biotechnology #biotech #pharmaceuticals #pharma #brilaroxazine #schizophrenia #CNS